首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2019年 1期 非肝硬化门静脉高压症的诊断与治疗 => 肝脏肿瘤 =>索拉非尼联合经肝动脉..
索拉非尼联合经肝动脉化疗栓塞术和射频消融对肝细胞癌患者生存期的影响
Effect of sorafenib combined with transcatheter arterial chemoembolization and radiofrequency ablation on the survival of patients with hepatocellular carcinoma
文章发布日期:2018年12月17日  来源:  作者:孙斌,杨晓珍,谢放,等  点击次数:576次  下载次数:67次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:目的分析索拉非尼联合经肝动脉化疗栓塞术(TACE)和射频消融(RFA)治疗肝细胞癌(HCC)患者的生存期及预后影响因素。方法回顾性分析2012年1月-2016年6月首都医科大学附属北京佑安医院收治的,分别接受索拉非尼单药治疗(n=30)、索拉非尼联合TACE(二联疗法,n=70),或者索拉非尼联合TACE和RFA(三联疗法,n=121)治疗的221例HCC患者的中位生存期及其预后影响因素。采用Kaplan-Meier法绘制生存曲线,log-rank检验生存曲线是否有差异,Cox比例风险回归模型进行生存率的影响因素分析;不同疗法治疗患者的Child-Pugh分级和BCLC分期比较,采用Wilcoxon秩和检验分析。结果接受三联疗法治疗患者的中位生存时间,较二联疗法(9.5个月 vs 43个月, χ2=12.77,P=0.000 4),或索拉非尼单药治疗组(9.5个月 vs 2.0个月, χ2=16.69,P<0.000 1)显著延长。影响疾病进展的危险因素包括患者年龄<60岁,BCLC分期C期,Child-Pugh分级B级、C级,血清AFP> 200 ng/ml,肿瘤低分化,肿瘤直径>5 cm,有微血管侵犯(MVI)或有肝外转移(EHS)的肝内肿瘤,以及未出现索拉非尼相关副作用(P值均<0.05)。结论索拉非尼联合TACE和RFA治疗可延长HCC患者的生存期。年龄<60岁和肿瘤负荷严重是影响HCC患者疾病进展的不良预后因素。
【Abstract】:ObjectiveTo analyze the effect of sorafenib combined with transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA) on the survival of patients with hepatocellular carcinoma (HCC) and its prognostic factors. MethodsA retrospective analysis was performed on 221 HCC patients who received sorafenib alone (group A), sorafenib plus TACE (group B), or sorafenib combined with TACE and RFA (group C) in Beijing YouAn Hospital, Capital Medical University, from January 2012 to June 2016 to investigate their median survival and its prognostic factors. The Kaplan-Meier method was used to plot a survival curve, and the log-rank test was used to test whether there was any difference in the survival curve; the Cox proportional-hazards regression model was used to analyze the influencing factors for survival rate; the Wilcoxon rank sum test was used to compare Child-Pugh class and Barcelona Clinic Liver Cancer (BCLC) stage between the patients treated with different therapies. ResultsGroup C had a significantly longer median survival than group B (9.5 months vs 4.3 months, χ2=12.77, P=0.000 4) and group A (9.5 months vs 2.0 months, χ2=16.69, P<0.000 1). The risk factors for disease progression were age <60 years, BCLC stage C, Child-Pugh class B, Child-Pugh class C, serum alpha-fetoprotein >200 ng/ml, poor tumor differentiation, tumor diameter >5 cm, and intrahepatic tumor with microvascular invasion or extrahepatic spread, as well as absence of sorafenib-related side events (all P<005). ConclusionSorafenib combined with TACE and RFA can prolong the survival of HCC patients. Age <60 years and severe tumor burden are poor prognostic factors for disease progression in HCC patients.
【关键字】:癌, 肝细胞; 化学栓塞, 治疗性; 导管消融术; 索拉非尼
【Key words】:carcinoma, hepatocellular; chemoembolization, therapeutic; catheter ablation; sorafenib
【引证本文】:SUN B, YANG XZ, XIE F, et al. Effect of sorafenib combined with transcatheter arterial chemoembolization and radiofrequency ablation on the survival of patients with hepatocellular carcinoma[J]. J Clin Hepatol, 2019, 35(1): 104-108. (in Chinese)
孙斌, 杨晓珍,谢放,等.索拉非尼联合经肝动脉化疗栓塞术和射频消融对肝细胞癌患者生存期的影响[J]. 临床肝胆病杂志, 2019, 35(1): 104-108.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号